Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Benefit of ADP receptor antagonists in atherothrombotic patients: New evidence
Autore:
Bogousslavsky, J;
Indirizzi:
Univ Lausanne, Dept Neurol, CH-1015 Lausanne, Switzerland Univ Lausanne Lausanne Switzerland CH-1015 CH-1015 Lausanne, Switzerland
Titolo Testata:
CEREBROVASCULAR DISEASES
, volume: 11, anno: 2001, supplemento:, 2
pagine: 5 - 10
SICI:
1015-9770(2001)11:<5:BOARAI>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-RISK PATIENTS; ANTIPLATELET THERAPY; DOUBLE-BLIND; ASPIRIN; CLOPIDOGREL; TICLOPIDINE; STENT; TRIAL; ANTICOAGULATION; THROMBOGENESIS;
Keywords:
atherothrombosis; clopidogrel;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Bogousslavsky, J CHU Vaudois, Serv Neurol, CH-1011 Lausanne, Switzerland CHU Vaudois Lausanne Switzerland CH-1011 e, Switzerland
Citazione:
J. Bogousslavsky, "Benefit of ADP receptor antagonists in atherothrombotic patients: New evidence", CEREB DIS, 11, 2001, pp. 5-10

Abstract

In the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial, clopidogrel showed a statistically significant superiority over aspirin in the prevention of ischaemic stroke, myocardial infarction and vascular death in patients with symptomatic atherosclerosis. More recently, post-hoc analysis of the data also showed that repeat hospitalization for ischaemic or bleeding events was decreased with clopidogrel compared with aspirin. Complementary analyses show that the benefit of clopidogrel overaspirin is amplified in a large population at very high risk of further atherothrombotic events (diabetics, patients with high cholesterol, and patients with previous manifestations of atherothrombosis). A potential clinically useful advantage of clopidogrel is its low propensity for adverse interaction with angiotensin-converting enzyme (ACE) inhibitors, contrary to whatmay be seen with aspirin, as observed in a post-hoc CAPRIE analysis. The putative aspirin-ACE inhibitor interaction is being tested prospectively in the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial - a randomized comparison of warfarin, clopidogrel and aspirin in patients with chronic heart failure. The good gastrointestinal tolerance of clopidogrel seen in CAPRIE has been further demonstrated in a study in healthy volunteers where there was a markedly lower gastroduodenal erosion score after 8 days' administration of clopidogrel 75 mg/day compared with aspirin 325mg/day (p < 0.001). Following the positive findings obtained with clopidogrel plus aspirin in the Clopidogrel Aspirin Stent International CooperativeStudy (CLASSICS) trial, other studies of clopidogrel plus aspirin have been initiated or are planned. These include Management of Atherothrombosis with Clopidogrel in High-risk patients (MATCH), a randomized comparison of clopidogrel plus aspirin versus clopidogrel in high-risk patients with recentstroke or transient ischaemic attack. Copyright (C) 2001 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 18:26:25